Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Lung Cancer

Free Subscription 12.08.2024 2 AJR Am J Roentgenol 1 Am J Respir Crit Care Med 9 Ann Surg Oncol 1 Arch Bronconeumol 8 BMC Cancer 2 Br J Cancer 1 Cancer 4 Cancer Sci 1 Chest 1 Clin Lung Cancer 4 Clin Nucl Med 1 Eur J Cardiothorac Surg 1 Int J Cancer 1 J Natl Cancer Inst 19 J Thorac Oncol 17 Lung Cancer 3 N Engl J Med 1 Oncologist 1 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AJR Am J Roentgenol

1. FINTELMANN FJ
   Editorial Comment: Percutaneous Core Needle Biopsy Is Safe and Accurate for Pulmonary Lesions Associated With Cystic Airspaces.
   AJR Am J Roentgenol. 2024;223:e2431481.
   PubMed        
   
   
2. BALBI M, Capelli S, Caroli A, Culasso NC, et al
   CT-Guided Core-Needle Biopsy of Pulmonary Lesions Associated With Cystic Airspaces: A Case-Control Study.
   AJR Am J Roentgenol. 2024 May 8. doi: 10.2214/AJR.24.31042.
   PubMed         Abstract available
   
   

   
   Am J Respir Crit Care Med

3. MOGHADDAM SJ, Document S, Savai R, Salehi-Rad R, et al
   Premalignant Progression in the Lung: Knowledge Gaps and Novel Opportunities for Interception of Non-Small Cell Lung Cancer. An Official American Thoracic Society Research Statement.
   Am J Respir Crit Care Med. 2024 Aug 8. doi: 10.1164/rccm.202406-1168.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

4. SIRAKAYA F, Calik Kutukcu E, Onur MR, Dikmen E, et al
   ASO Author Reflections: Is the VATS Technique Superior to Thoracotomy Techniques in Terms of Respiratory Muscle Function and Functional Exercise Capacity?
   Ann Surg Oncol. 2024;31:5768-5769.
   PubMed        
   
   
5. YASAR S, Yilmaz F, Utkan G, Algin E, et al
   Analysis of Treatment Strategies and Outcomes in Malignant Peritoneal Mesothelioma: Insights From a Multi-Center Study.
   Ann Surg Oncol. 2024;31:6228-6236.
   PubMed         Abstract available
   
   
6. FUJIWARA W, Yotsukura M, Yoshida Y, Nakagawa K, et al
   Clinical and Pathologic Differences between Small-Cell Carcinoma and Large-Cell Neuroendocrine Carcinoma of the Lung.
   Ann Surg Oncol. 2024;31:5697-5705.
   PubMed         Abstract available
   
   
7. JIA J, Zhang G, Wei L, Qi L, et al
   The Battle for Accuracy: Identifying the Most Effective Grading System for Lung Invasive Mucinous Adenocarcinoma.
   Ann Surg Oncol. 2024;31:5717-5728.
   PubMed         Abstract available
   
   
8. VAN HAREN RM, Kovacic MB, Delman AM, Pratt CG, et al
   Disparities Associated with Decision to Undergo Oncologic Surgery: A Prospective Mixed-Methods Analysis.
   Ann Surg Oncol. 2024;31:5757-5764.
   PubMed         Abstract available
   
   
9. OHTANI-KIM SJ, Samejima J, Wakabayashi M, Tada M, et al
   What is the Optimal Resection Extent for Preserving Respiratory Function in Segmentectomy?: Insights on Lung Resection Volume and Respiratory Function.
   Ann Surg Oncol. 2024;31:5766-5767.
   PubMed        
   
   
10. YASAR S
    ASO Author Reflections: Analysis of Treatment Strategies and Outcomes in Malignant Peritoneal Mesothelioma: Insights from a Multi-center Study.
    Ann Surg Oncol. 2024;31:6276-6277.
    PubMed        
    
    
11. NAGANO T, Takada K, Narutomi F, Kinoshita F, et al
    Clinical Significance of SIRPalpha Expression on Tumor-Associated Macrophages in Patients with Lung Squamous Cell Carcinoma.
    Ann Surg Oncol. 2024;31:6309-6319.
    PubMed         Abstract available
    
    
12. OHTANI-KIM SJ, Samejima J, Wakabayashi M, Tada M, et al
    ASO Visual Abstract: Effect of Resected Lung Volume on Pulmonary Function and Residual Lung Volume in Patients Undergoing Segmentectomy-A Retrospective Study.
    Ann Surg Oncol. 2024;31:5783-5784.
    PubMed        
    
    

    
    Arch Bronconeumol

13. PAPAVASSILIOU KA, Gogou VA, Papavassiliou AG
    Harnessing Tumor Mechanobiology in NSCLC Treatment.
    Arch Bronconeumol. 2024;60:523-525.
    PubMed        
    
    

    
    BMC Cancer

14. QIN H, Yan H, Chen Y, Xu Q, et al
    Clinical outcomes for immune checkpoint inhibitors plus chemotherapy in non-small-cell lung cancer patients with uncommon driver gene alterations.
    BMC Cancer. 2024;24:952.
    PubMed         Abstract available
    
    
15. GARRIDO J, Bernal Y, Gonzalez E, Blanco A, et al
    Beyond tobacco: genomic disparities in lung cancer between smokers and never-smokers.
    BMC Cancer. 2024;24:951.
    PubMed         Abstract available
    
    
16. YAO N, Qin Z, Chen M, Hu L, et al
    Effects of brain radiotherapy strategies on survival in the era of MRI for patients with limited stage small cell lung cancer.
    BMC Cancer. 2024;24:953.
    PubMed         Abstract available
    
    
17. AKDOGAN O, Ogut B, Sutcuoglu O, Sert A, et al
    The impact of the expression level of growth differentiation factor 15 in tumor tissue on the response to immunotherapy in non-small cell lung cancer.
    BMC Cancer. 2024;24:954.
    PubMed         Abstract available
    
    
18. KENNEDY K, Jusue-Torres I, Buller ID, Rossi E, et al
    Neighborhood-level deprivation and survival in lung cancer.
    BMC Cancer. 2024;24:959.
    PubMed         Abstract available
    
    
19. ZHANG J, Lv PY, Zhao X, Liu ML, et al
    Real-world effectiveness and safety of recombinant human endostatin plus PD-1 inhibitors and chemotherapy as first-line treatment for EGFR/ALK-negative, advanced or metastatic non-small cell lung cancer.
    BMC Cancer. 2024;24:967.
    PubMed         Abstract available
    
    
20. MA Z, Liu Y, Bao Y, Liu Q, et al
    Higher immune cell radiation dose is correlated with poor tumor control and survival in patients with non-small cell lung cancer receiving postoperative radiotherapy.
    BMC Cancer. 2024;24:968.
    PubMed         Abstract available
    
    
21. SUN V, Guthrie KA, Arnold KB, Antonoff M, et al
    Comparative effectiveness of perioperative physical activity in older adults with lung cancer and their family caregivers: design of a multicenter pragmatic randomized trial.
    BMC Cancer. 2024;24:976.
    PubMed         Abstract available
    
    

    
    Br J Cancer

22. BUDCZIES J, Romanovsky E, Kirchner M, Neumann O, et al
    KRAS and TP53 co-mutation predicts benefit of immune checkpoint blockade in lung adenocarcinoma.
    Br J Cancer. 2024;131:524-533.
    PubMed         Abstract available
    
    
23. NAGELBERG AL, Sihota TS, Chuang YC, Shi R, et al
    Integrative genomics identifies SHPRH as a tumor suppressor gene in lung adenocarcinoma that regulates DNA damage response.
    Br J Cancer. 2024;131:534-550.
    PubMed         Abstract available
    
    

    
    Cancer

24. NIERENGARTEN MB
    ASCO 2024: Advances in lung cancer treatments and care: A new standard of care therapy based on the results of the LAURA study underscores the need for testing for epidermal growth factor receptor (EGFR) mutations in patients with unresectable stage I
    Cancer. 2024;130:2894.
    PubMed        
    
    

    
    Cancer Sci

25. LI C, Hu M, Cai S, Yang G, et al
    Dysfunction of CD8(+) T cells around tumor cells leads to occult lymph node metastasis in NSCLC patients.
    Cancer Sci. 2024;115:2528-2539.
    PubMed         Abstract available
    
    
26. SHI Y, Zhang J, Li J, He J, et al
    USP15, activated by TFAP4 transcriptionally, stabilizes SHC1 via deubiquitination and deteriorates renal cell carcinoma.
    Cancer Sci. 2024;115:2617-2629.
    PubMed         Abstract available
    
    
27. FUJIKAWA Y, Kawabata S, Tsujino K, Yamada H, et al
    Boron neutron capture therapy delays the decline in neurological function in a mouse model of metastatic spinal tumors.
    Cancer Sci. 2024;115:2774-2785.
    PubMed         Abstract available
    
    
28. ONDA N, Nakamichi S, Hirao M, Matsuda K, et al
    Afatinib plus PEM and CBDCA overcome osimertinib resistance in EGFR-mutated NSCLC with high thrombospondin-1 expression.
    Cancer Sci. 2024;115:2718-2728.
    PubMed         Abstract available
    
    

    
    Chest

29. VLACHOS E, Fox A, Dell'Italia J, Maurice N, et al
    Healthcare provider practices and perceptions of biomarker testing in U.S. Veterans with non-small cell lung cancer.
    Chest. 2024 Aug 2:S0012-3692(24)04886-4. doi: 10.1016/j.chest.2024.
    PubMed        
    
    

    
    Clin Lung Cancer

30. RECK M, De T, Paz-Ares L, Edmondson-Jones M, et al
    Treatment-Switching Adjustment of Overall Survival in CheckMate 227 Part 1 Evaluating First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy for Metastatic Nonsmall Cell Lung Cancer.
    Clin Lung Cancer. 2024 Jun 29:S1525-7304(24)00131.
    PubMed         Abstract available
    
    

    
    Clin Nucl Med

31. YANG L, Dong Z, Wei L, Chen F, et al
    Simple Pulmonary Eosinophilia Mimicking Lung Metastases on 18F-FDG PET/CT.
    Clin Nucl Med. 2024 Jun 21. doi: 10.1097/RLU.0000000000005339.
    PubMed         Abstract available
    
    
32. PUROHIT P, Preet K, Mittal BR, Kumar R, et al
    FDG PET/CT in an Interesting Case of Paraneoplastic Relapsing Polychondritis Associated With Adenocarcinoma of the Lung.
    Clin Nucl Med. 2024 Aug 1. doi: 10.1097/RLU.0000000000005345.
    PubMed         Abstract available
    
    
33. XIE Y, Ma J, Tang W, Zhang Y, et al
    Efficacy and Safety Evaluation of 177Lu-FAP-2286 in the Treatment of Advanced Lung Cancer.
    Clin Nucl Med. 2024;49:830-837.
    PubMed         Abstract available
    
    
34. SAHAFI P, Sabertanha A, Ataei Azimi S, Aryana K, et al
    A Case of Metastatic Pulmonary Calcification Detected on 99mTc-MDP Bone Scan and 99mTc-FAPI Scan.
    Clin Nucl Med. 2024;49:e441-e443.
    PubMed         Abstract available
    
    

    
    Eur J Cardiothorac Surg

35. TENG M, Yi C, Yang W, Zhang J, et al
    Sleeve lobectomy versus pneumonectomy following neoadjuvant therapy in patients with non-small cell lung cancer.
    Eur J Cardiothorac Surg. 2024 Aug 9:ezae300. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    Int J Cancer

36. CHEN S, Cheng S, Cai J, Liu Z, et al
    The current therapeutic cancer vaccines landscape in non-small cell lung cancer.
    Int J Cancer. 2024 Aug 7. doi: 10.1002/ijc.35088.
    PubMed         Abstract available
    
    

    
    J Natl Cancer Inst

37. KATKI HA, Prorok PC, Castle PE, Minasian LM, et al
    Increasing power in screening trials by testing control-arm specimens: application to multicancer detection screening.
    J Natl Cancer Inst. 2024;116:1280-1287.
    PubMed         Abstract available
    
    

    
    J Thorac Oncol

38. TRISOLINI R
    The Devil Is in the Details: A Hidden Obstacle to Implementing the Proposed Revision of the N Descriptors in the Ninth Edition of the TNM Classification for Lung Cancer.
    J Thorac Oncol. 2024;19:e23.
    PubMed        
    
    
39. PONVILAWAN B, Subramanian J, Bansal D
    The Number of Chemoimmunotherapy Cycles and Clinical Outcomes in Resectable NSCLC.
    J Thorac Oncol. 2024;19:e24-e26.
    PubMed        
    
    
40. HUANG J, Osarogiagbon RU
    Author's Reply.
    J Thorac Oncol. 2024;19:e24.
    PubMed        
    
    
41. CAMERON RB, Hines JB, Torri V, Garassino MC, et al
    A Response Letter by Cameron et al.
    J Thorac Oncol. 2024;19:e26-e28.
    PubMed        
    
    
42. KOSAKA N, Kataoka Y
    Letter Regarding "Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRASG12C-Mutated NSCLC Treated With Sotorasib".
    J Thorac Oncol. 2024;19:e28.
    PubMed        
    
    
43. ERNST SM, von der Thusen JH, Dubbink HJ, Dingemans AC, et al
    Letter Regarding "Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRASG12C-Mutated NSCLC Treated With Sotorasib".
    J Thorac Oncol. 2024;19:e29-e30.
    PubMed        
    
    
44. KUBO N
    Response to Letter to the Editor.
    J Thorac Oncol. 2024;19:e22.
    PubMed        
    
    
45. SHI L, Bao Z
    Accurate Prognostic Factor for Carbon-Ion Radiotherapy in Operable Stage I NSCLC.
    J Thorac Oncol. 2024;19:e21-e22.
    PubMed        
    
    
46. SILVESTRI GA, Young RP, Tanner NT, Mazzone P, et al
    Screening Low-Risk Individuals for Lung Cancer: The Need May Be Present, but the Evidence of Benefit Is Not.
    J Thorac Oncol. 2024;19:1155-1163.
    PubMed         Abstract available
    
    
47. MAKAREM M, Janne PA
    "Tumor-Free Survival" Outweighs the Side Effects of Combined Anti-EGF Therapy and Chemotherapy in Patients With NSCLC.
    J Thorac Oncol. 2024;19:1151-1154.
    PubMed        
    
    
48. ZHENG MM, Wu YL
    "Tumor-free survival" Does Not Outweigh the Adverse Effects of Anti-EGFR Therapy and Chemotherapy in Patients With NSCLC.
    J Thorac Oncol. 2024;19:1146-1150.
    PubMed        
    
    
49. LAISAAR T, Innos K, Jaal J, Oselin K, et al
    Lung Cancer in Estonia.
    J Thorac Oncol. 2024;19:1138-1145.
    PubMed        
    
    
50. WOODARD GA, Jablons DM
    Shades of Gray: Do Never Smokers Benefit From Lung Cancer Screening Programs?
    J Thorac Oncol. 2024;19:1135-1137.
    PubMed        
    
    
51. TURK MA
    Editorial Comment: Validation Study for the N Descriptor of the Newly Proposed 9th Edition of the TNM Staging System Proposed by the International Association for the Study of Lung Cancer.
    J Thorac Oncol. 2024;19:1133-1134.
    PubMed        
    
    
52. PERRONE F, Leonetti A, Tiseo M, Facchinetti F, et al
    Benefit With No Target: Long-Term Outcomes of Chemoimmunotherapy in "PD-L1 Negative" NSCLC.
    J Thorac Oncol. 2024;19:1128-1132.
    PubMed        
    
    
53. GRAY SG, Mutti L, Meirson T
    Encouraging Fussy Eaters in EGFR-Mutated Lung Cancer.
    J Thorac Oncol. 2024;19:1125-1127.
    PubMed        
    
    
54. HUBER RM, Cavic M, Balata H, Kitts AB, et al
    From the IASLC Early Detection and Screening Committee Terminology Issues in Screening and Early Detection of Lung Cancer - IASLC Early Detection and Screening Committee Expert Group Recommendations.
    J Thorac Oncol. 2024 Aug 2:S1556-0864(24)00747.
    PubMed         Abstract available
    
    
55. HU LY, Zhuang WT, Chen MJ, Liao J, et al
    EGFR Oncogenic Mutations in NSCLC Impair Macrophage Phagocytosis and Mediate Innate Immune Evasion Through Up-Regulation of CD47.
    J Thorac Oncol. 2024;19:1186-1200.
    PubMed         Abstract available
    
    
56. WOLF AS, Eisele M, Giroux DJ, Gill R, et al
    The International Association for the Study of Lung Cancer Pleural Mesothelioma Staging Project: Expanded Database to Inform Revisions in the Ninth Edition of the TNM Classification of Pleural Mesothelioma.
    J Thorac Oncol. 2024;19:1242-1252.
    PubMed         Abstract available
    
    

    
    Lung Cancer

57. GALLINA FT, Balzano V, Porciello N, Taje R, et al
    Trajectory of PD-L1 expression in a patient underwent neoadjuvant chemo-immunotherapy for resectable NSCLC.
    Lung Cancer. 2024;194:107900.
    PubMed        
    
    
58. BARGHOUT SH, Zhan LJ, Raptis S, Al-Agha F, et al
    Treatment patterns and outcomes in KRAS(G12C)-positive advanced NSCLC patients previously treated with immune checkpoint inhibitors: A Canada-wide real-world, multi-center, retrospective cohort study.
    Lung Cancer. 2024;194:107898.
    PubMed         Abstract available
    
    
59. OYA Y, Imaizumi K, Mitsudomi T
    The next-generation KRAS inhibitors...What comes after sotorasib and adagrasib?
    Lung Cancer. 2024;194:107886.
    PubMed         Abstract available
    
    
60. WESPISER M, Swalduz A, Perol M
    Treatment sequences in EGFR mutant advanced NSCLC.
    Lung Cancer. 2024;194:107895.
    PubMed         Abstract available
    
    
61. WANG Q, Liu H, Xu Z, Zhang L, et al
    Effects of pregabalin combined with tramadol/paracetamol on acute pain in patients with CT-guided puncture localization of pulmonary nodules.
    Lung Cancer. 2024;194:107888.
    PubMed         Abstract available
    
    
62. HUANG S, Cao C, Guo L, Li C, et al
    Comparison of the variability and diagnostic efficacy of respiratory-gated PET/CT based radiomics features with ungated PET/CT in lung lesions.
    Lung Cancer. 2024;194:107889.
    PubMed         Abstract available
    
    
63. DOUMA LH, Baas P, de Gooijer CJ
    First-line doublet immunotherapy: Game changer or hype for patients with mesothelioma?
    Lung Cancer. 2024;194:107891.
    PubMed        
    
    
64. XU Y, Zhang Y, Qiang H, Zhong H, et al
    Impact of PD-L1 expression on the efficacy of first-line crizotinib in advanced ROS1-rearranged NSCLC.
    Lung Cancer. 2024;194:107892.
    PubMed         Abstract available
    
    
65. NIEDERMAIER B, Kou Y, Tong E, Eichinger M, et al
    CT-guided needle biopsy is not associated with increased ipsilateral pleural metastasis.
    Lung Cancer. 2024;194:107890.
    PubMed         Abstract available
    
    
66. SPEEL EM, Dafni U, Thunnissen E, Hendrik Ruschoff J, et al
    ROS1 fusions in resected stage I-III adenocarcinoma: Results from the European Thoracic Oncology Platform Lungscape project.
    Lung Cancer. 2024;194:107860.
    PubMed         Abstract available
    
    
67. KIM YJ, Kim S, Kim TM, Suh KJ, et al
    A phase II study of osimertinib in patients with NSCLC harboring EGFR exon 20 insertion: A multicenter trial of the Korean Cancer Study Group (LU17-19).
    Lung Cancer. 2024;194:107870.
    PubMed         Abstract available
    
    
68. BYLICKI O, Guisier F, Scherpereel A, Daniel C, et al
    Real-World efficacy and safety of combination nivolumab plus ipilimumab for Untreated, Unresectable, pleural Mesothelioma: The Meso-Immune (GFPC 04-2021) trial.
    Lung Cancer. 2024;194:107866.
    PubMed         Abstract available
    
    
69. OGAWA H, Koga T, Pham NA, Bernards N, et al
    Clinical and pathological predictors of engraftment for patient-derived xenografts in lung adenocarcinoma.
    Lung Cancer. 2024;194:107863.
    PubMed         Abstract available
    
    
70. PROVENCIO M, Robado de Lope L, Serna-Blasco R, Nadal E, et al
    BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC.
    Lung Cancer. 2024;194:107865.
    PubMed         Abstract available
    
    
71. ARRIETA O, Caballe-Perez E, Hernandez-Pedro N, Romero-Nunez E, et al
    Prevalence of pathogenic or likely pathogenic germline variants in cancer predisposition genes among selected patients with lung adenocarcinoma: The GERMLUNG study.
    Lung Cancer. 2024;194:107864.
    PubMed         Abstract available
    
    
72. CASIRAGHI M, Cara A, Mazzella A, Girelli L, et al
    1000 Robotic-assisted lobectomies for primary lung cancer: 16 years single center experience.
    Lung Cancer. 2024;195:107903.
    PubMed         Abstract available
    
    
73. TAMIYA A, Osuga M, Harada D, Isa SI, et al
    Mechanisms of resistance and correlation between pre-treatment co-alterations and p-prognosis to osimertinib in chemo-naive advanced non-small cell lung cancer.
    Lung Cancer. 2024;195:107917.
    PubMed         Abstract available
    
    

    
    N Engl J Med

74. CASCONE T, Spicer JD, Provencio Pulla M
    Perioperative Nivolumab in Resectable Lung Cancer. Reply.
    N Engl J Med. 2024;391:573-574.
    PubMed        
    
    
75. SORSCHER S
    Perioperative Nivolumab in Resectable Lung Cancer.
    N Engl J Med. 2024;391:573.
    PubMed        
    
    
76. SOBRERO S, Vaisitti F, Leo F
    Perioperative Nivolumab in Resectable Lung Cancer.
    N Engl J Med. 2024;391:572-573.
    PubMed        
    
    

    
    Oncologist

77. MACK PC, Keller-Evans RB, Li G, Lofgren KT, et al
    Real-World Clinical Performance of a DNA-Based Comprehensive Genomic Profiling Assay for Detecting Targetable Fusions in Nonsquamous NSCLC.
    Oncologist. 2024;29:e984-e996.
    PubMed         Abstract available
    
    

    
    PLoS One

78. ITO M, Koido S, Iwamoto T, Morimoto S, et al
    Enhancing the immunogenicity of Wilms tumor 1 epitope in mesothelioma cells with immunoproteasome inhibitors.
    PLoS One. 2024;19:e0308330.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.